Searched for
VIIV HEALTHCARE
GSK to buy RAPT Therapeutics in $2.2 billion deal for promising food allergy therapyBritain's GSK is set to acquire RAPT Therapeutics for $2.2 billion. This move brings the experimental food allergy drug ozureprubart into G...- Aurobindo to produce, supply long acting HIV treatment drugAurobindo Pharma will manufacture and supply long-acting injectable HIV treatment, cabotegravir, across 133 countries through a voluntary l...
- Lupin gets USFDA nod for generic HIV drugLupin has received tentative approval from the USFDA to market a generic HIV drug in the US under PEPFAR. The drug, made at Lupin's Nagpur ...
- European Commission authorises GSK's HIV prevention drugCabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acqu...
- Smallcap pharma stock jumps over 11% as arm receives tentative USFDA approval for HIV drug DolutegravirThe company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with the USFDA, of whic...
- Aurobindo, Cipla, Viatris in licensing pact with MPP to make ViiV's HIV preventive therapyThrough the MPP-ViiV Healthcare agreement, the three generic manufacturers will be able to develop, manufacture, and supply generic version...
- On World AIDS Day, South Africa finds hope in new treatmentA new drug, Cabotegravir, has been proven to be 90 per cent more effective than the daily pill known as PrEP against AIDS. Cabotegravir is ...
- Aurobindo Pharma gets USFDA nod for anti-HIV drugAurobindo Pharma has received tentative approval from the USFDA for dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, use...
- Lupin launches generic HIV drug in US marketThe company had earlier received approval from the United States Food and Drug Administration for Abacavir and Lamivudine tablets 600 mg/30...
- Activists cry foul over new HIV drug monopolyOnly one Indian drug maker, Emcure, will be allowed to sell the medicine in the Indian private market, because of a licensing agreement wit...
- Lupin gets USFDA approval to market HIV drug; stock upLupin moved higher in trade as the Mumbai-based drug maker got a tentative approval from the USFDA to market Darunavir Ethanolate tablets.
- Lupin gets USFDA nod for HIV drugDrug firm Lupin has received tentative approval from the US health regulator to market a generic version of Prezista tablets, used in treat...
- Lupin rallies over 1% on acquisition plans, USFDA HIV drug approvalLupin Ltd rallied as much as 1.5 per cent in trade on Monday on reports that that the drug major is eyeing acquisitions in various global m...
- Lupin gets USFDA approval for HIV drugThe Mumbai-based firm has received final approval from the US Food and Drug Administration for its Lamivudine tablets in strengths of 150 m...
- Lupin launches HIV drug in the US with marketing exclusivityLupin launched the generic version of ViiV Healthcare's Trizivir tablets in the US market with 180-days of marketing exclusivity.
- Lupin gets USFDA nod to market HIV drug in the US marketThe company's product is indicated in combination with other antiretrovirals or alone for the treatment of HIV-1 infection, it added.
- Aurobindo Pharma gets USFDA approval for HIV drugAurobindo Pharma said it has received US health regulator's final approval to market Abacavir Tablets, used in the treatment of HIV in the ...
- Hetero Labs to produce Gilead's HIV drugs, through Medicines Patent PoolHyderabad based Hetero labs through an agreement with Geneva based Medicines Patent Pool will produce four key HIV drugs developed by Gilea...
- ViiV Healthcare seeks partners for HIV drug in IndiaGlobal drugmaker ViiV Healthcare is evaluating local partnerships to launch its patented HIV medicine maraviroc in India and is open to a d...
- Glaxo takes new AIDS drug into final-stage testsGlaxoSmithKline and its partner Shionogi are progressing a new drug against HIV into final-stage clinical testing, ramping up competition i...
Load More
